Phase I/II trial of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

Cancer

Volumn 85, Issue 8, 1999, Pages 1828-1842

  Juweid, Malik E ^a   Hajjar, George ^a   Swayne, Lawrence C ^a   Sharkey, Robert M ^a   Suleiman, Samer ^a   Herskovic, Thomas ^b   Pereira, Michael ^b   Rubin, Arnold D ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

Author keywords

Carcinoembryonic antigen; Dosimetry; Medullary thyroid carcinoma; Monoclonal antibodies; Radioimmunoconjugates; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IODINE 131;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSIMETRY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; MALE; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGED; NECK DISSECTION; NEOPLASM PROTEINS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS; THYROIDECTOMY; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0033561012     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H     Document Type: Article

References (25)

1. Wells SA Jr., Dilley WG, Farndon JA, Leight GS, Baylin SB. Early diagnosis and treatment of medullary carcinoma. Arch Intern Med 1985;145:1248-52.
2. Busnardo B, Girelli ME, Simioni N, Macamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984;53:278-85.
3. Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer 1976;34:111-5.
4. Wells SA Jr., Haagensen DE Jr., Linehan WM, Farrel RE, Dilley WG. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer 1978;42:1498-1503.
5. Peltier P, Curtet C, Chatal JF, Fouddsl JML, Daniel G, Aillet G, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993; 34:1267-73.
6. 2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 1992;74:157-63.
7. Edington HD, Watson CG, Levine G, Tauxe WN, Yousem SA, Unger M, et al. Radioiminunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium-111-labeled monoclonal antibody to CEA. Surgery 1988;104: 1004-10.
8. Zanin DEA, van Dongen A, Hoefnagel CA, Bruning PF. Radioimmunoscintigraphy using iodine-131-anti-CEA monoclonal antibodies and thallium-201 scintigraphy in medullary thyroid carcinoma: a case report. J Nucl Med 1990;31: 1854-5.
9. Reiners CH, Eilles CH, Spiegel W, Becker W, Borner W. Immunoscintigraphy in medullary thyroid cancer using an I-123 or In-111-labelled monoclonal anti-CEA antibody fragment. J Nucl Med 1986;25:227-31.
10. 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1995;55:5946s-5951s.
11. Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209-17.
12. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996;37:905-11.
13. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-92.
14. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-85.
15. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawly KD, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2082-96.
16. 2. Cancer 1996;78:157-68.
17. Hoffman T. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Office of Biologics Research and Review, Center for Drugs and Biologics, Food and Drug Administration, 1987 [memorandum, Rockville, MD].
18. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1989;31:508-11.
19. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50:1039s-1042s.
20. Siegel JA, Goldenberg DM, Sharkey RM, Hall TC, Murthy S, Lee RE, et al. Tumor and organ dosimetry for I-131-labeled LL2 (EPB2) monoclonal antibody in patients with B-cell lymphomas. Antibody Immunoconj Radiopharm 1990;4:649-54.
21. Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide. MIRD Pamphlet No. 1, revised. New York, Society of Nuclear Medicine, 1976.
22. Sgouros G. Bone marrow dosimetry for radioimmunotherapy. theoretical considerations. J Nucl Med 1993;34:689-94.
23. Dunn RM, Juweid M, Sharkey RM, Behr TM, Goldenberg DM. Can occult metastases be treated by radioimmunotherapy? Cancer 1997;80(Suppl):2656-69.
24. Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55(Suppl):5935-45.
25. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D, et al. External radiotherapy in thyroid cancer. Cancer 1985;55:2062-71.